<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02192944</url>
  </required_header>
  <id_info>
    <org_study_id>FTM1401</org_study_id>
    <nct_id>NCT02192944</nct_id>
  </id_info>
  <brief_title>Comparison of the ECG Effects Related to Pharmacokinetic Profile of Chloroquine and Piperaquine</brief_title>
  <official_title>Comparison of the Electrocardiographic Effects in Relation to Pharmacokinetic Profile of Chloroquine and Piperaquine in Healthy Thai Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chloroquine and piperaquine are the two most widely used antimalarial drugs ever. Hundreds of&#xD;
      millions of people have received these drugs. Both are structurally similar and have&#xD;
      cardiovascular effect. While there are no concerns over the use of chloroquine, regulatory&#xD;
      authorities have suggested restrictions on the use of piperaquine.&#xD;
&#xD;
      We have recently completed a series of cross-over clinical and pharmacokinetic evaluations of&#xD;
      chloroquine, piperaquine, pyronaridine and primaquine in healthy subjects. These studied were&#xD;
      approved by the ethical committee of FTM. All drugs were well tolerated with no clinically&#xD;
      significant ECG changes. Four subjects were in two studies. This offers a unique opportunity&#xD;
      to compare the electrocardiographic effects of chloroquine and piperaquine in the same&#xD;
      subjects and therefore characterize the concentration-effect relationships, and thus relative&#xD;
      safety.&#xD;
&#xD;
      We propose to extend the previous subject study to recruit 16 subjects including those who&#xD;
      have received either piperaquine or chloroquine in our previous studies so that 20 subjects&#xD;
      received both drugs for a crossover comparison. The blood sampling schedule and&#xD;
      electrocardiograms would be exactly the same as previously but would finish at 24 hours.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator team has recently completed two cross-over clinical and pharmacokinetic&#xD;
      evaluations chloroquine and piperaquine in healthy subjects i.e. Study A and Study B.&#xD;
&#xD;
      Study A: Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of&#xD;
      Orally Administered Primaquine and Chloroquine in Healthy Thai Adult Subjects&#xD;
&#xD;
      Study B: Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally&#xD;
      Administered Primaquine and Dihydroartemisinin-Piperaquine in Healthy Adult Subjects&#xD;
&#xD;
      Four subjects were in both studies. The investigator proposes to extend the previous subject&#xD;
      study to recruit 16 subjects including but not limited to those who have received either&#xD;
      chloroquine from study A or piperaquine form study B in our previous studies so that 20&#xD;
      subjects received both drugs for a crossover comparison.&#xD;
&#xD;
      Subjects who were previously enrolled into study A that received a single dose of 600 mg&#xD;
      chloroquine base will receive a single dose of piperaquine phosphate (in form of 120/960 mg&#xD;
      dihydroartemisinin-piperaquine) in this study. The subjects who were previously enrolled into&#xD;
      study B that received a single dose of piperaquine phosphate (in form of 120/960 mg&#xD;
      dihydroartemisinin-piperaquine) will receive a single dose of 600 mg of chloroquine base in&#xD;
      this study.&#xD;
&#xD;
      The investigator team may recruit naive subject in case, the team can't reach total number of&#xD;
      20 subjects.&#xD;
&#xD;
      The total duration for each subject's participation in the study is approximately 3 weeks for&#xD;
      subject who challenges only one study drug or 11 weeks for subject who challenges both drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of QTc within 24 hours after dosing</measure>
    <time_frame>24 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>24 hours after dosing</time_frame>
    <description>Area under the curve within 24 hours after dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participant with adverse event</measure>
    <time_frame>24 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Chloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chloroquine base 600 mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dihydroartemisinin-piperaquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dihydroartemisinin-piperaquine 120/960 mg single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.</description>
    <arm_group_label>Dihydroartemisinin-piperaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-piperaquine</intervention_name>
    <description>Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.</description>
    <arm_group_label>Chloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy as judged by a responsible physician with no abnormality identified on a&#xD;
             medical evaluation including medical history and physical examination&#xD;
&#xD;
          2. Male and female subjects aged between 18 years to 60 years.&#xD;
&#xD;
          3. A female is eligible to enter and participate in this study if she is:&#xD;
&#xD;
               -  of non-childbearing potential including pre-menopausal females with documented&#xD;
                  (medical report verification) hysterectomy or double oophorectomy&#xD;
&#xD;
               -  or postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of&#xD;
                  spontaneous amenorrhea with serum follicle stimulating hormone levels &gt;40 mIU/mL&#xD;
                  or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy&#xD;
&#xD;
               -  or of childbearing potential, has a negative serum pregnancy test at screening&#xD;
                  and prior to start the study drug in each period, and abstain from sexual&#xD;
                  intercourse or agrees to using effective contraceptive methods (e.g.,&#xD;
                  intrauterine device, hormonal contraceptive drug, tubal ligation or female&#xD;
                  barrier method with spermicide) until study completion.&#xD;
&#xD;
          4. A male is eligible to enter and participate in this study if he: agrees to abstain&#xD;
             from (or use a condom during) sexual intercourse with females of childbearing&#xD;
             potential or lactating females; or is willing to use a condom/spermicide, until study&#xD;
             completion.&#xD;
&#xD;
          5. Normal electrocardiogram (ECG) with QTc &lt; 450 msec.&#xD;
&#xD;
          6. Provide a signed and dated written informed consent prior to study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, trying to get pregnant, or are lactating.&#xD;
&#xD;
          2. The subject has evidence of active substance abuse that may compromise safety,&#xD;
             pharmacokinetics, or ability to adhere with protocol instructions.&#xD;
&#xD;
          3. A positive pre-study hepatitis B surface antigen, positive hepatitis C antibody, or&#xD;
             positive human immunodeficiency virus-1 (HIV-1) antibody result at screening.&#xD;
&#xD;
          4. Subjects with a personal history of hypertension, cardiac disease, symptomatic or&#xD;
             asymptomatic arrhythmias, syncopal episodes, or additional risk factors for torsades&#xD;
             de points (heart failure, hypokalemia).&#xD;
&#xD;
          5. Subjects with a family history of sudden cardiac death.&#xD;
&#xD;
          6. A creatinine clearance &lt;70 mL/min as determined by Cockcroft-Gault equation:&#xD;
&#xD;
             CLcr (mL/min) = (140 - age) * Wt / (72 * Scr) (multiply answer by 0.85 for females)&#xD;
             Where age is in years, weight (wt) is in kg, and serum creatinine (Scr) is in units of&#xD;
             mg/dL [Cockcroft, 1976].&#xD;
&#xD;
          7. History of alcohol or substance abuse or dependence within 6 months of the study:&#xD;
             History of regular alcohol consumption averaging &gt;7 drinks/wk for women or &gt;14&#xD;
             drinks/wk for men. One drink is equivalent to 12 g alcohol = 5 oz (150 mL) of wine or&#xD;
             12 oz (360 mL) of beer or 1.5 oz (45 mL) of 80 proof distilled spirits within 6 months&#xD;
             of screening.&#xD;
&#xD;
          8. Use of prescription or non-prescription drugs except paracetamol at doses of up to 2&#xD;
             grams/day, including vitamins, herbal and dietary supplements (including St. John's&#xD;
             Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5&#xD;
             half-lives (whichever is longer) prior to the first dose of study medication until the&#xD;
             completion of the follow-up procedure, unless in the opinion of investigator, the&#xD;
             medication will not interfere with the study procedures or compromise subject safety.&#xD;
&#xD;
          9. The subject has participated in a clinical trial and has received a drug or a new&#xD;
             chemical entity within 30 days or 5 half lives, or twice the duration of the&#xD;
             biological effect of any drug (whichever is longer) prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
         10. The subject is unwilling to abstain from ingesting alcohol within 48 hours prior to&#xD;
             the first dose of study medication until collection of the final pharmacokinetic&#xD;
             sample.&#xD;
&#xD;
         11. Subjects who have donated blood to the extent that participation in the study would&#xD;
             result in more than 300 mL blood donated within a 30-day period. Note: This does not&#xD;
             include plasma donation.&#xD;
&#xD;
         12. Subjects who have a history of allergy to the study drug or drugs of this class, or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator,&#xD;
             contraindicates participation in the trial. In addition, if heparin is used during&#xD;
             pharmacokinetic sampling, subjects with a history of sensitivity to heparin or&#xD;
             heparin-induced thrombocytopenia should not be enrolled.&#xD;
&#xD;
         13. Those who, in the opinion of the investigator, have a risk of non-compliance with&#xD;
             study procedures.&#xD;
&#xD;
         14. AST or ALT &gt;1.5 upper limit of normal (ULN).&#xD;
&#xD;
         15. Subjects with history of renal disease, hepatic disease, and/or cholecystectomy.&#xD;
&#xD;
         16. Abnormal methaemoglobin level.&#xD;
&#xD;
         17. Subjects who have anemia, Hb &lt;12 for both male and female&#xD;
&#xD;
         18. History of antimalarial drugs use within 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Borimas Hanboonkunupakarn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Tropical Medicine, Mahidol University, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Tropical Medicine, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>July 1, 2014</study_first_submitted>
  <study_first_submitted_qc>July 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2014</study_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ECG</keyword>
  <keyword>Pharmacokinetic profile</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Artenimol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02192944
org study id: FTM1401
nct id: NCT02192944
lead sponsor: 
has dmc: No
Chloroquine and piperaquine are the two most widely used antimalarial drugs ever. Hundreds of
      millions of people have received these drugs. Both are structurally similar and have
      cardiovascular effect. While there are no concerns over the use of chloroquine, regulatory
      authorities have suggested restrictions on the use of piperaquine.

      We have recently completed a series of cross-over clinical and pharmacokinetic evaluations of
      chloroquine, piperaquine, pyronaridine and primaquine in healthy subjects. These studied were
      approved by the ethical committee of FTM. All drugs were well tolerated with no clinically
      significant ECG changes. Four subjects were in two studies. This offers a unique opportunity
      to compare the electrocardiographic effects of chloroquine and piperaquine in the same
      subjects and therefore characterize the concentration-effect relationships, and thus relative
      safety.

      We propose to extend the previous subject study to recruit 16 subjects including those who
      have received either piperaquine or chloroquine in our previous studies so that 20 subjects
      received both drugs for a crossover comparison. The blood sampling schedule and
      electrocardiograms would be exactly the same as previously but would finish at 24 hours.
The investigator team has recently completed two cross-over clinical and pharmacokinetic
      evaluations chloroquine and piperaquine in healthy subjects i.e. Study A and Study B.

      Study A: Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of
      Orally Administered Primaquine and Chloroquine in Healthy Thai Adult Subjects

      Study B: Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally
      Administered Primaquine and Dihydroartemisinin-Piperaquine in Healthy Adult Subjects

      Four subjects were in both studies. The investigator proposes to extend the previous subject
      study to recruit 16 subjects including but not limited to those who have received either
      chloroquine from study A or piperaquine form study B in our previous studies so that 20
      subjects received both drugs for a crossover comparison.

      Subjects who were previously enrolled into study A that received a single dose of 600 mg
      chloroquine base will receive a single dose of piperaquine phosphate (in form of 120/960 mg
      dihydroartemisinin-piperaquine) in this study. The subjects who were previously enrolled into
      study B that received a single dose of piperaquine phosphate (in form of 120/960 mg
      dihydroartemisinin-piperaquine) will receive a single dose of 600 mg of chloroquine base in
      this study.

      The investigator team may recruit naive subject in case, the team can't reach total number of
      20 subjects.

      The total duration for each subject's participation in the study is approximately 3 weeks for
      subject who challenges only one study drug or 11 weeks for subject who challenges both drugs.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Health Services Research
masking: None (Open Label)
measure: Changes of QTc within 24 hours after dosing
time frame: 24 hours after dosing
measure: Area under the curve
time frame: 24 hours after dosing
description: Area under the curve within 24 hours after dosing
measure: Number of participant with adverse event
time frame: 24 hours after dosing
arm group label: Chloroquine
arm group type: Active Comparator
description: Chloroquine base 600 mg single dose
arm group label: Dihydroartemisinin-piperaquine
arm group type: Active Comparator
description: Dihydroartemisinin-piperaquine 120/960 mg single dose
intervention type: Drug
intervention name: Chloroquine
description: Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
arm group label: Dihydroartemisinin-piperaquine
intervention type: Drug
intervention name: Dihydroartemisinin-piperaquine
description: Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
arm group label: Chloroquine
criteria: 
gender: All
minimum age: 18 Years
maximum age: 60 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Borimas Hanboonkunupakarn, MD
role: Principal Investigator
affiliation: Faculty of Tropical Medicine, Mahidol University, Thailand
facility: 
country: Thailand
responsible party type: Sponsor
mesh term: Chloroquine
mesh term: Piperaquine
mesh term: Artenimol